The first drug profiled, etomidate, has been improved by researchers at Massachusetts General Hospital. The researchers were able to improve the drug so that it does not interfere with the immune system, a current side effect of the agent.
The second, remimazolam, is a new benzodiazepine-type sedative drug with predictable effects and a comparatively rapid recovery time.
More Articles on Anesthesia:
FDA Approves Mylan’s Generic Anesthesia Drug Etomidate
Improving Perioperative Efficiency, Quality Requires Nursing-Anesthesia Partnership
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
